Revenue: As of FY2025 Q2, the actual value is USD 131 K.EPS: As of FY2025 Q2, the actual value is USD -0.01.<h3>Segment Revenue</h3><ul><li>Research and Other Revenue: For the three months ended June 30, 2025, revenue was $131,000, compared to $510,000 for the same period in 2024. For the six months ended June 30, 2025, revenue was $506,000, compared to $794,000 for the same period in 2024.</li></ul><h3>Operational Metrics</h3><ul><li>Net Loss: The net loss for the three months ended June 30, 2025 was $15.4 million, compared to $17.9 million for the same period in 2024. For the six months ended June 30, 2025, the net loss was $34.7 million, compared to $36.2 million for the same period in 2024.</li><li>Research and Development Expenses: For the three months ended June 30, 2025, R&amp;D expenses were $7.4 million, compared to $8.3 million for the same period in 2024. For the six months ended June 30, 2025, R&amp;D expenses were $15.8 million, compared to $16.2 million for the same period in 2024.</li><li>General and Administrative Expenses: For the three months ended June 30, 2025, G&amp;A expenses were $7.5 million, compared to $9.7 million for the same period in 2024. For the six months ended June 30, 2025, G&amp;A expenses were $16.8 million, compared to $17.8 million for the same period in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Operating Cash Flow: Net cash used in operating activities for the six months ended June 30, 2025 was $16.1 million, compared to $28.6 million for the same period in 2024.</li><li>Investing Cash Flow: Net cash used in investing activities for the six months ended June 30, 2025 was $397,000, compared to $760,000 for the same period in 2024.</li><li>Financing Cash Flow: Net cash provided by financing activities for the six months ended June 30, 2025 was $24.2 million, compared to $29.2 million for the same period in 2024.</li></ul><h3>Unique Metrics</h3><ul><li>Convertible Notes at Fair Value: As of June 30, 2025, the fair value of convertible notes was $38.5 million, compared to $34.2 million as of December 31, 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company plans to continue its focus on the DCVax-L and DCVax-Direct programs, including preparations for Phase II trials and expansion of manufacturing capacity.</li><li>Non-Core Business: The company is exploring potential compassionate use programs in the US and expanding its existing program in the UK.</li><li>Priority: The company is actively engaged in the MAA process for DCVax-L in the UK and plans to announce results upon completion of the regulatory review.</li></ul>

Northwest Biotherapeutics, Inc. | 10-Q: FY2025 Q2 Revenue: USD 131 K